Neurocrine Biosciences Offers Insights on Major Depressive Disorder Study
Neurocrine Biosciences, Inc. (Nasdaq: NBIX) has released important findings regarding its Phase 2 study for the investigational compound NBI-1070770 aimed at treating adults suffering from major depressive disorder (MDD). While the primary objectives were not met, the company is focused on understanding the data for future guidance.
Overview of the Phase 2 Study
The Phase 2 study, which included 73 participants with a confirmed diagnosis of MDD and inadequate response to at least one antidepressant, was designed as a signal-seeking trial. Although it did not achieve its primary endpoint, the results still provide valuable data for further investigation.
Neurocrine's Chief Medical Officer, Dr. Sanjay Keswani, expressed gratitude towards those involved in the study and emphasized the need to thoroughly analyze the findings to determine subsequent steps. This phase of research signifies a continued commitment to exploring innovative treatments for mental health conditions.
Understanding NBI-1070770
NBI-1070770 is characterized as a selective, orally active negative allosteric modulator targeting the NR2B subunit of the NMDA receptor. This therapeutic approach represents a novel method in the evolving landscape of psychiatric treatments.
Neurocrine Biosciences obtained the rights to NBI-1070770 from Takeda Pharmaceutical Company, signaling a strong partnership for developing groundbreaking therapies for depression.
Clinical Study Design and Objectives
The multicenter, randomized, double-blind study stratified participants into groups receiving NBI-1070770 and placebo. The main goal was to measure changes in depression severity from baseline to Day 5 using the Montgomery-Åsberg Depression Rating Scale (MADRS). The study's structured approach aimed to establish clear metrics for evaluating the compound's effectiveness.
Importance of Tackling Major Depressive Disorder
Major depressive disorder is a critical mental health issue defined by persistent mood disturbances, diminished interest in daily activities, and significant energy depletion. It ranks among the leading causes of disability globally. Data indicates that over 21 million Americans suffer from MDD, with nearly half experiencing inadequate relief from standard antidepressant therapies. Addressing this treatment gap remains crucial.
About Neurocrine Biosciences, Inc.
Neurocrine Biosciences is a dedicated biopharmaceutical organization focused on neuroscience. The company aims to develop transformative therapies for individuals confronting complex neurological and psychiatric conditions. Its portfolio encompasses FDA-approved products treating various neurological disorders, along with a robust range of investigational compounds advancing in clinical trials.
For additional information, you can visit the official Neurocrine Biosciences website and discover more about their innovative endeavors in science and patient care.
Frequently Asked Questions
What is NBI-1070770?
NBI-1070770 is an investigational compound designed as a potential treatment for major depressive disorder, aiming to modulate NMDA receptors.
What were the findings of the Phase 2 study?
The Phase 2 study did not meet its primary endpoint, however, Neurocrine is focusing on the data collected for future analysis.
How many participants were involved in the study?
Seventy-three adults diagnosed with major depressive disorder participated in the Phase 2 study.
What is the significance of the study for patients?
This study represents an effort to provide new treatment options for those suffering from depression, a condition affecting millions.
Where can I learn more about Neurocrine Biosciences?
Visit Neurocrine Biosciences' official website for comprehensive information about their research and available treatments.
